---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-103925"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:39:56.438735+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ironwood amends credit facility to $550M, extends maturity to 2028; declines CNP-104 option

## Summary
- Revolving credit facility increased from $500M to $550M; $400M outstanding as of amendment date.
- Maturity extended to earlier of Dec 31, 2028 or 91 days before convertible notes maturity, subject to liquidity.
- Maximum consolidated secured net leverage ratio raised to 3.50x (initial period), stepping down to 3.00x; can rise further for acquisitions over $50M.
- Ironwood will not exercise option for CNP-104 (primary biliary cholangitis); collaboration with COUR terminates, no further rights or obligations.

## SEC filing metadata
- accession: 0001104659-24-103925
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924103925/0001104659-24-103925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924103925/tm2425053d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-103925
- JSON: https://secwatch.observer/filing/0001104659-24-103925.json
- Plain text: https://secwatch.observer/filing/0001104659-24-103925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.